BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30718124)

  • 1. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
    Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
    Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
    Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
    Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
    Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
    PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study.
    Aarnio R; Östensson E; Olovsson M; Gustavsson I; Gyllensten U
    BMC Cancer; 2020 Jul; 20(1):645. PubMed ID: 32660432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
    Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
    Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Offering Cervical Cancer Screening with HPV Self-Sampling among African-American Women in the Mississippi Delta.
    Campos NG; Scarinci IC; Tucker L; Peral S; Li Y; Regan MC; Sy S; Castle PE; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1114-1121. PubMed ID: 33771846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of cervical cancer screening strategies based on the Papanicolaou smear test in Korea.
    Ko MJ; Kim J; Kim Y; Lee YJ; Hong SR; Lee JK
    Asian Pac J Cancer Prev; 2015; 16(6):2317-22. PubMed ID: 25824757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
    Vijayaraghavan A; Efrusy MB; Goodman KA; Santas CC; Huh WK
    Gynecol Oncol; 2010 Nov; 119(2):237-42. PubMed ID: 20713299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and costs of using HPV testing to screen for cervical cancer.
    Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
    JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico.
    Flores YN; Bishai DM; Lorincz A; Shah KV; Lazcano-Ponce E; Hernández M; Granados-García V; Pérez R; Salmerón J
    Cancer Causes Control; 2011 Feb; 22(2):261-72. PubMed ID: 21170578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
    Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
    Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
    Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
    BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
    Kim JJ; Wright TC; Goldie SJ
    J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.